IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Callahan Advisors LLC

Callahan Advisors LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 35,719 shares of the medical research company's stock after purchasing an additional 3,506 shares during the period. Callahan Advisors LLC's holdings in IQVIA were worth $7,019,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Capital Performance Advisors LLP purchased a new position in IQVIA in the 3rd quarter worth $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. boosted its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after buying an additional 196 shares during the last quarter. Finally, Concord Wealth Partners purchased a new position in IQVIA during the 3rd quarter worth approximately $57,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company's stock, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

IQV has been the topic of a number of research reports. Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. cut their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday. Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Finally, Leerink Partners reaffirmed an "outperform" rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $251.22.

IQVIA Stock Up 0.2 %

Shares of IQVIA stock traded up $0.48 during trading on Friday, hitting $194.49. 116,964 shares of the stock were exchanged, compared to its average volume of 1,363,938. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm's 50-day moving average price is $199.73 and its 200 day moving average price is $216.79. The stock has a market cap of $34.25 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.86 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.